Company · LLY
Healthcare · 1 research article
Delayed up to 15 min · Source: Finnhub · Not investment advice
Lilly’s revenue grew 39% and guidance rose, but two drugs supplied 88% of growth, price fell 15%, and $4.57 a share of acquired R&D held non-GAAP EPS growth to 7%.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| LLY Eli Lilly | LONG | +39% | +7% | raised | Oct 29, 2026 | |
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | Compare |
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | Compare |
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | Compare |
| HUM Humana | LONG | — | — | — | — | Compare |
| ISRG Intuitive Surgical | LONG | +22% | — | issued | Oct 20, 2026 | Compare |
| MRK Merck | LONG | — | — | issued | Oct 29, 2026 | Compare |
| PFE Pfizer | LONG | — | — | — | — | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
